Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical review

1 Jan 2023

Abstract excerpt

a non-irreversible mechanism. This review covers the fourth-generation EGFR-TKIs' most recent design with their essential binding interactions, the clinical difficulties, and the potential outcomes of treating patients with EGFR mutation C797S resistant to third-generation EGFR-TKIs was also discussed. Moreover, the utilization of various therapeutic strategies, including multi-targeting drugs and combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37350862
DOI: 10.1039/d3ra02347h

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Insights into fourth generation selective inhibitors of (C797S) EGFR mutation combating non-small cell lung cancer resistance: a critical reviewPMID 37350862Read ↗

The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation.Semantic proximity Read ↗

Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.Semantic proximity Read ↗

Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC.Semantic proximity Read ↗

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.Semantic proximity Read ↗

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy.Semantic proximity Read ↗

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC.Semantic proximity Read ↗

Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor InhibitorsSemantic proximity Read ↗

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and PerspectiveSemantic proximity Read ↗

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.Semantic proximity Read ↗

[Mechanism and clinical efficacy of third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.